AMACR and benign prostatic hyperplasia: Extending our previous research investigating biomarkers that are clinically important to distinguish patients with prostate cancer at risk for early relapse from patients in clinical remission [12-14], in this study, we analyzed by RT-PCR assays p503S, p504S and p510S gene markers in PB from 42 patients with treated or untreated CaP and with benign prostatic hyperplasia (BPH) (controls).